Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors

NCT05123209 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Liver Cancer

Interventions

BIOLOGICAL: IM83 CAR-T cells
COMBINATION_PRODUCT: The second-line treatment of liver cancer

Sponsor

Beijing Immunochina Medical Science & Technology Co., Ltd.